Aaron Weitzman

2.4k citations

38 papers · 1.2k indexed · 1 hit paper · h-index 15

Impact in

Hematology top 1%
- Chronic Myeloid Leukemia Treatments
Genetics top 2%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Oncology 14
- Cancer Treatment and Pharmacology 9
- CAR-T cell therapy research 3
Genetics 13
- Chronic Lymphocytic Leukemia Research 12

Co-authors: Francis J. Giles (7 shared papers)Hagop M. Kantarjian (8 shared papers)Philipp le Coutre (9 shared papers)Yaping Shou (4 shared papers)Andreas Hochhaus (8 shared papers)Kapil N. Bhalla (6 shared papers)Norbert Gattermann (5 shared papers)Md Ariful Haque (5 shared papers)
Journals: Journal of Clinical Oncology (15 papers)Blood (7 papers)Cancer Research (2 papers)Annals of Oncology (2 papers)Investigational New Drugs (1 paper)
Partner nations: United States Germany United Kingdom

In The Last Decade

Aaron Weitzman

37 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance 2007 · 540 citations

Peers

Countries citing papers authored by Aaron Weitzman

Since Specialization

Citations

This map shows the geographic impact of Aaron Weitzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Weitzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Weitzman more than expected).

Fields of papers citing papers by Aaron Weitzman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Weitzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Weitzman. The network helps show where Aaron Weitzman may publish in the future.

Co-authors

The 25 scholars most cited alongside Aaron Weitzman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aaron Weitzman Line = papers co-authored together Aaron Weitzman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood ·Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann, Kapil N. Bhalla, Giuliana Alimena, Francesca Palandri, Gert J. Ossenkoppele, Franck-Emmanuel Nicolini, Stephen G. O’Brien, Mark R. Litzow, Ravi Bhatia, Francisco Cervantes, Md Ariful Haque, Yaping Shou, Debra Resta, Aaron Weitzman, Andreas Hochhaus, Philipp le Coutre Hit paper breakdown →	2007	540
2	UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia Leukemia ·Jonathan B. Singer, Yaping Shou, Francis J. Giles, H Kantarjian, Yanzhi Hsu, Anna Robeva, P. Rae, Aaron Weitzman, Joanne M. Meyer, Margaret Dugan, Oliver G. Ottmann	2007	91
3	Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. PubMed ·Daniel P. Petrylak, Robert B. MacArthur, Jacqueline M. O’Connor, Gary Shelton, Aaron Weitzman, Timothy Judge, C England-Owen, Nancy Zuech, Charles Pfaff, Jeffrey H. Newhouse, Emilia Bagiella, D Hetjan, Ihor Sawczuk, Mitchell C. Benson, Carl A. Olsson	1999	74
4	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma British Journal of Cancer ·Adil Daud, Harriet M. Kluger, Razelle Kurzrock, Frauke Schimmöller, Aaron Weitzman, Thomas A. Samuel, Ali H. Moussa, Michael S. Gordon, Geoffrey I. Shapiro	2017	52
5	DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER The Journal of Urology ·Aaron Weitzman, Gary Shelton, Nancy Zuech, Cindy E. Owen, Timothy Judge, Mitchell C. Benson, Ihor S. Sawczuk, Aaron E. Katz, Carl A. Olsson, Emilia Bagiella, Charles Pfaff, Jeffrey H. Newhouse, Daniel P. Petrylak	2000	50
6	Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial JAMA Oncology ·Amylou C. Dueck, Howard I. Scher, Antonia V. Bennett, Gina L. Mazza, Gita Thanarajasingam, Gisela Schwab, Aaron Weitzman, Lauren J. Rogak, Ethan Basch	2019	43
7	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). Journal of Clinical Oncology ·Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, Sylvestre Le Moulec, Stéphane Oudard, Ugo De Giorgi, Michael Krainer, Andries M. Bergman, Wolfgang Hoelzer, Ronald de Wit, Martin Boegemann, Fred Saad, Giorgio Cruciani, Antoine Thiery Vuillemin, Susan Feyerabend, Kurt Miller, David A. Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi	2015	32
8	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort European Urology ·Ethan Basch, Karen A. Autio, Matthew R. Smith, Antonia V. Bennett, Aaron Weitzman, Christian Scheffold, Christopher J. Sweeney, Dana E. Rathkopf, David C. Smith, Daniel J. George, Celestia S. Higano, Andrea Harzstark, Oliver Sartor, Michael S. Gordon, Nicholas J. Vogelzang, Johann S. de Bono, Naomi B. Haas, Paul G. Corn, Frauke Schimmöller, Howard I. Scher	2014	31
9	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). Journal of Clinical Oncology ·Ethan Basch, Mark C. Scholz, Johann S. de Bono, Nicholas J. Vogelzang, Paul L. de Souza, Gavin Marx, Ulka N. Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Antonarakis, Joe M. O’Sullivan, Arash Rezazadeh Kalebasty, Kim N., Robert Dreicer, Thomas E. Hutson, Milan Mangeshkar, Jaymes Holland, Aaron Weitzman, Howard I. Scher	2015	31
10	Phase I and Pharmacokinetic Study of LY293111, an Orally Bioavailable LTB₄ Receptor Antagonist, in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Gary K. Schwartz, Aaron Weitzman, Eileen M. O’Reilly, Les Brail, Dinesh P. de Alwis, Ann Cleverly, Barbara Barile-Thiem, Vincent Vinciguerra, Daniel R. Budman	2005	26
11	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Investigational New Drugs ·Tara Baetz, Elizabeth A. Eisenhauer, Lillian L. Siu, Martha MacLean, Karen Doppler, Wendy Walsh, B. Fisher, Azhar Khan, Dinesh P. de Alwis, Aaron Weitzman, Leslie H. Brail, Malcolm Moore	2006	25
12	Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer The Breast ·Amy Tiersten, Jennifer Y. Wo, Caron A. Jacobson, Aaron Weitzman, Tamara B. Horwich, Charles Hesdorffer, David G. Savage, Andrea B. Troxel	2004	18
13	A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Patients with Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC) Who Have Also Failed Dasatinib Therapy. Blood ·Francis J. Giles, Philipp le Coutre, Kapil N. Bhalla, Gianantonio Rosti, G.J. Ossenkopplele, Giuliana Alimena, Aaron Weitzman, Teresa Rafferty, Ming Zheng, Hagop M. Kantarjian	2006	18
14	A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). Blood ·Hagop M. Kantarjian, Norbert Gattermann, Andreas Hochhaus, Richard A. Larson, Teresa Rafferty, Aaron Weitzman, Md Ariful Haque, Francis J. Giles, S G O'Brien, Philipp le Coutre	2006	18
15	A Phase II Study of Nilotinib, a Novel Tyrosine Kinase Inhibitor Administered to Imatinib Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Blast Crisis (BC) or Relapsed/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL). Blood ·Oliver G. Ottmann, Hagop M. Kantarjian, Richard A. Larson, Philipp le Courte, Michele Baccarani, Teresa Rafferty, Aaron Weitzman, Francis J. Giles	2006	17
16	The relation of plasma total homocysteine levels to prevalent cardiovascular disease in older patients with ischemic stroke Aging Clinical and Experimental Research ·Abraham Adunsky, Aaron Weitzman, Y. Fleissig, L. Levenkrohn, M. Arad, Ram Doolman, S Gavendo, Ben‐Ami Sela	2000	13
17	A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP) Journal of Clinical Oncology ·G. Rosti, Philipp le Coutre, Kapil N. Bhalla, F. Giles, G. J. Ossenkoppele, Andreas Hochhaus, Norbert Gattermann, Md Ariful Haque, Aaron Weitzman, Michele Baccarani, Hagop M. Kantarjian	2007	13
18	Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology ·Adil Daud, Harriet M. Kluger, Gerald M. Edelman, Michael S. Gordon, Frauke Schimmöller, Aaron Weitzman, Thomas A. Samuel, Ali H. Moussa, Keith T. Flaherty, Geoffrey I. Shapiro	2013	12
19	First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology ·Johanna C. Bendell, Lawrence Fong, Mark N. Stein, Tomasz M. Beer, Ashley E. Ross, Xīn Gào, Aaron Weitzman, Richard J. Austin, Vaishnavi Ganti, Che‐Leung Law, Bryan D. Lemon, Holger Wesche, Johann S. de Bono	2020	12
20	A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib Journal of Clinical Oncology ·Francis J. Giles, Philipp le Coutre, Kapil N. Bhalla, G. Rosti, G. J. Ossenkoppele, G. Alimena, Aaron Weitzman, Ming Zheng, Hagop M. Kantarjian	2007	12

About Aaron Weitzman

Aaron Weitzman is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Hematology and Rheumatology, having authored 38 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers), Eosinophilic Disorders and Syndromes (10 papers), Cancer Treatment and Pharmacology (9 papers), Prostate Cancer Treatment and Research (9 papers), Advanced Breast Cancer Therapies (4 papers), Acute Lymphoblastic Leukemia research (3 papers) and CAR-T cell therapy research (3 papers). The work is most often cited by research in Hematology (687 citations), Genetics (570 citations), Rheumatology (421 citations), Oncology (329 citations) and Pulmonary and Respiratory Medicine (259 citations). Aaron Weitzman has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Francis J. Giles, Hagop M. Kantarjian, Philipp le Coutre, Yaping Shou, Andreas Hochhaus, Kapil N. Bhalla, Norbert Gattermann, Md Ariful Haque, Giuliana Alimena and Gert J. Ossenkoppele. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer Research, Annals of Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact